FindTrial
Sign In

Effectiveness of Ayurvedic Formulation Patanjali Aurogrit in subjects with Breast Cancer.

Evaluate the efficacy of Indian Ayurvedic Formulation Aurogrit in subjects with Breast Cancer: A Single-Arm, Open-Label, Prospective, Interventional Study - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058318
Enrollment
100
Registered
2023-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

None listed

Sponsors

Patanjali Research Foundation governed by Patanjali Research Foundation Trust
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects diagnosed with Breast Cancer. Subjects Aged 18 years and above. Willing to participate and give consent for the study. Capability for complete compliance and completion of follow-up

Exclusion criteria

Exclusion criteria: Male subjects with breast cancer. Subjects diagnosed with Metastatic breast cancer. Subjects with other co-morbidities, such as CVD, liver abnormalities, and HIV. Assessment by the investigator as being unable or unwilling to comply with the requirements of the protocol. The subjects with complications and requiring surgical interventions. Pregnant or Lactating women and women intenting to become pregnant

Design outcomes

Primary

MeasureTime frame
Evaluating the Efficacy and changesin clinical lab parameters, radiological imaging and efficacy outcomesof Aurogrit in subjects diagnosed with Breast cancerTimepoint: Baseline, Day 30, Day 60 and Day 90—

Secondary

MeasureTime frame
Incidence of treatment-related symptoms and assessment of health-related quality of life (HRQOL) as measured using the European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) questionnaire, DASS-21, BR23 and BRECON 23 questionnaireTimepoint: Baseline, Day 30, Day 60 and Day 90—

Countries

India

Contacts

Public ContactDr Bhawna sharma

Patanjali Research Foundation

drdevasenabamsmd@gmail.com07012421624

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026